Spotlight Innovation Inc  

(Public, OTCMKTS:STLT)   Watch this stock  
Find more results for OTC:AEXP
0.000 (0.00%)
Feb 23 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.08 - 0.58
Open     -
Vol / Avg. 0.00/17,233.00
Mkt cap 5.21M
P/E     -
Div/yield     -
EPS -0.65
Shares 34.29M
Beta -3.57
Inst. own 0%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -211665.90% -
Operating margin -203668.10% -
EBITD margin - -
Return on average assets -97.80% -212.97%
Return on average equity - -
CDP Score - -


11147 Aurora Ave Bldg 3
URBANDALE, IA 50322-7904
United States - Map
+1-515-2749087 (Phone)

Website links


Spotlight Innovation Inc. is a pharmaceutical company. The Company is focused on acquiring the intellectual property rights to therapeutics designed to address unmet medical needs. As of June 30, 2017, the Company had four subsidiaries: Celtic Biotech Iowa, Inc. (Celtic Iowa), Caretta Therapeutics, LLC (Caretta), SMA Therapeutics, LLC (SMA), and Zika Therapeutics, LLC (Zika). It is focused on various diseases, including cancer, pain management, Zika Virus infection and spinal muscular atrophy. The Company, through Celtic Iowa, holds interest in Celtic Biotech Limited, which is engaged in developing specialized compounds derived from snake venom, for the treatment of solid cancers and cancer imaging. The Company, through Caretta, is focused on developing the commercialization of over-the-counter products. It is also engaged in discovery, synthetic modification, and preclinical validation of drug-like compounds intended to treat patients with Zika virus infection.

Officers and directors

John Michael Krohn Chairman of the Board, President, Interim Chief Executive Officer, Chief Operating Officer
John William Pim CPA Chief Financial Officer
Age: 62
Sanjeev Agarwal Director
Age: 58
Ralph Arthur Director
Age: 69
June Beetler Director
Craig A. Lang Director
Age: 60